9 research outputs found

    The Veterans Health Administration: Quality, Value, Accountability, and Information as Transforming Strategies for Patient-Centered Care

    Get PDF
    Abstract Countries around the world are in need of electronic medical record (EMR) systems that meet their specific needs. This paper describes briefly the benefits of EMRs in developing countries. It focuses on the basic EMR information, including types of EMRs, components of EMRs, and already existing EMRs, in order to establish which EMR systems would be feasible and effective for specific situations. Electronic Medical Record Systems for Developing Countries: Review Structure of Systems A. Data Model • Flat file structures (spread-sheet like) as compared with relational databases B. Networks • Stand-alone • Systems which are deployed on a single machine • Local area networks • Wide area network solutions • Deployed across a much larger area Discussion When choosing which electronic medical record system to implement, one should consider the following factors: population, location, and availability of resources. OpenMRS may be the best choice for today's EMR

    Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity

    No full text
    Insulin resistance (IR) is a metabolic disorder characterized by impaired insulin signaling and cellular glucose uptake. The current paradigm for insulin signaling centers upon the insulin receptor (InsR) and its substrate IRS1; the latter is believed to be the sole conduit for postreceptor signaling. Here we challenge that paradigm and show that GIV/Girdin, a guanidine exchange factor (GEF) for the trimeric G protein Gαi, is another major hierarchical conduit for the metabolic insulin response. By virtue of its ability to directly bind InsR, IRS1, and phosphoinositide 3-kinase, GIV serves as a key hub in the immediate postreceptor level, which coordinately enhances the metabolic insulin response and glucose uptake in myotubes via its GEF function. Site-directed mutagenesis or phosphoinhibition of GIV-GEF by the fatty acid/protein kinase C-theta pathway triggers IR. Insulin sensitizers reverse phosphoinhibition of GIV and reinstate insulin sensitivity. We also provide evidence for such reversible regulation of GIV-GEF in skeletal muscles from patients with IR. Thus GIV is an essential upstream component that couples InsR to G-protein signaling to enhance the metabolic insulin response, and impairment of such coupling triggers IR. We also provide evidence that GIV-GEF serves as therapeutic target for exogenous manipulation of physiological insulin response and reversal of IR in skeletal muscles
    corecore